Ekatherine Asatiani

First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

Eric J. Feldman, Jeffrey E. Lancet, Jonathan E. Kolitz et al. · Journal of Clinical Oncology · 2011 · 300 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +17

Deletion, Methylation, and Expression of the <i>NKX3.1</i> Suppressor Gene in Primary Human Prostate Cancer

Ekatherine Asatiani, Wen-Xin Huang, Antai Wang et al. · Cancer Research · 2005 · 159 citations · Full text

Medicine, Molecular Genetics, Oncology +6

Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis

Sameer A. Parikh, Hagop M. Kantarjian, Aaron D. Schimmer et al. · Clinical Lymphoma Myeloma & Leukemia · 2010 · 87 citations

Medicine, Hematology, Pharmacology +14

Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)

Andrea Necchi, Damien Pouessel, Raya Leibowitz‐Amit et al. · Annals of Oncology · 2018 · 54 citations · Full text

Medicine, Oncology, Urology +17

Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation

Jörge E. Cortes, Ronald Paquette, Moshe Talpaz et al. · Blood · 2008 · 51 citations

Medicine, Hematology, Oncology +14